444 related articles for article (PubMed ID: 25683269)
1. Cross-talk between ER and HER2 regulates c-MYC-mediated glutamine metabolism in aromatase inhibitor resistant breast cancer cells.
Chen Z; Wang Y; Warden C; Chen S
J Steroid Biochem Mol Biol; 2015 May; 149():118-27. PubMed ID: 25683269
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer.
Chen Z; Yuan YC; Wang Y; Liu Z; Chan HJ; Chen S
Breast Cancer Res Treat; 2015 Jul; 152(1):29-39. PubMed ID: 26026468
[TBL] [Abstract][Full Text] [Related]
3. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
Hole S; Pedersen AM; Hansen SK; Lundqvist J; Yde CW; Lykkesfeldt AE
Int J Oncol; 2015 Apr; 46(4):1481-90. PubMed ID: 25625755
[TBL] [Abstract][Full Text] [Related]
4. AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studies.
Wong C; Wang X; Smith D; Reddy K; Chen S
Breast Cancer Res Treat; 2012 Jul; 134(2):671-81. PubMed ID: 22706627
[TBL] [Abstract][Full Text] [Related]
5. Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
Ribas R; Pancholi S; Rani A; Schuster E; Guest SK; Nikitorowicz-Buniak J; Simigdala N; Thornhill A; Avogadri-Connors F; Cutler RE; Lalani AS; Dowsett M; Johnston SR; Martin LA
Breast Cancer Res; 2018 Jun; 20(1):44. PubMed ID: 29880014
[TBL] [Abstract][Full Text] [Related]
6. Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer.
Kazi AA; Gilani RA; Schech AJ; Chumsri S; Sabnis G; Shah P; Goloubeva O; Kronsberg S; Brodie AH
Breast Cancer Res; 2014 Jan; 16(1):R15. PubMed ID: 24472707
[TBL] [Abstract][Full Text] [Related]
7. GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.
Morandi A; Martin LA; Gao Q; Pancholi S; Mackay A; Robertson D; Zvelebil M; Dowsett M; Plaza-Menacho I; Isacke CM
Cancer Res; 2013 Jun; 73(12):3783-95. PubMed ID: 23650283
[TBL] [Abstract][Full Text] [Related]
8. AR collaborates with ERα in aromatase inhibitor-resistant breast cancer.
Rechoum Y; Rovito D; Iacopetta D; Barone I; Andò S; Weigel NL; O'Malley BW; Brown PH; Fuqua SA
Breast Cancer Res Treat; 2014 Oct; 147(3):473-85. PubMed ID: 25178514
[TBL] [Abstract][Full Text] [Related]
9. Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer.
Osipo C; Meeke K; Cheng D; Weichel A; Bertucci A; Liu H; Jordan VC
Int J Oncol; 2007 Feb; 30(2):509-20. PubMed ID: 17203234
[TBL] [Abstract][Full Text] [Related]
10. AIB1:ERα transcriptional activity is selectively enhanced in aromatase inhibitor-resistant breast cancer cells.
O'Hara J; Vareslija D; McBryan J; Bane F; Tibbitts P; Byrne C; Conroy RM; Hao Y; Gaora PÓ; Hill AD; McIlroy M; Young LS
Clin Cancer Res; 2012 Jun; 18(12):3305-15. PubMed ID: 22550166
[TBL] [Abstract][Full Text] [Related]
11. MYC regulates the unfolded protein response and glucose and glutamine uptake in endocrine resistant breast cancer.
Shajahan-Haq AN; Cook KL; Schwartz-Roberts JL; Eltayeb AE; Demas DM; Warri AM; Facey CO; Hilakivi-Clarke LA; Clarke R
Mol Cancer; 2014 Oct; 13():239. PubMed ID: 25339305
[TBL] [Abstract][Full Text] [Related]
12. HOXB7 Is an ERα Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance.
Jin K; Park S; Teo WW; Korangath P; Cho SS; Yoshida T; Győrffy B; Goswami CP; Nakshatri H; Cruz LA; Zhou W; Ji H; Su Y; Ekram M; Wu Z; Zhu T; Polyak K; Sukumar S
Cancer Discov; 2015 Sep; 5(9):944-59. PubMed ID: 26180042
[TBL] [Abstract][Full Text] [Related]
13. AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.
Ribas R; Pancholi S; Guest SK; Marangoni E; Gao Q; Thuleau A; Simigdala N; Polanska UM; Campbell H; Rani A; Liccardi G; Johnston S; Davies BR; Dowsett M; Martin LA
Mol Cancer Ther; 2015 Sep; 14(9):2035-48. PubMed ID: 26116361
[TBL] [Abstract][Full Text] [Related]
14. Cancer stem-like properties of hormonal therapy-resistant breast cancer cells.
Uchiumi K; Tsuboi K; Sato N; Ito T; Hirakawa H; Niwa T; Yamaguchi Y; Hayashi SI
Breast Cancer; 2019 Jul; 26(4):459-470. PubMed ID: 30610551
[TBL] [Abstract][Full Text] [Related]
15. Life following aromatase inhibitors--where now for endocrine sequencing?
Johnston SR; Martin LA; Dowsett M
Breast Cancer Res Treat; 2005; 93 Suppl 1():S19-25. PubMed ID: 16247596
[TBL] [Abstract][Full Text] [Related]
16. Alteration of Y-box binding protein-1 expression modifies the response to endocrine therapy in estrogen receptor-positive breast cancer.
Ito T; Kamijo S; Izumi H; Kohno K; Amano J; Ito K
Breast Cancer Res Treat; 2012 May; 133(1):145-59. PubMed ID: 21863258
[TBL] [Abstract][Full Text] [Related]
17. Contribution of Estrone Sulfate to Cell Proliferation in Aromatase Inhibitor (AI) -Resistant, Hormone Receptor-Positive Breast Cancer.
Higuchi T; Endo M; Hanamura T; Gohno T; Niwa T; Yamaguchi Y; Horiguchi J; Hayashi S
PLoS One; 2016; 11(5):e0155844. PubMed ID: 27228187
[TBL] [Abstract][Full Text] [Related]
18. The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer.
Gilani RA; Kazi AA; Shah P; Schech AJ; Chumsri S; Sabnis G; Jaiswal AK; Brodie AH
Breast Cancer Res Treat; 2012 Oct; 135(3):681-92. PubMed ID: 22878889
[TBL] [Abstract][Full Text] [Related]
19. Compensatory role of insulin-like growth factor 1 receptor in estrogen receptor signaling pathway and possible therapeutic target for hormone therapy-resistant breast cancer.
Iida M; Tsuboi K; Niwa T; Ishida T; Hayashi SI
Breast Cancer; 2019 May; 26(3):272-281. PubMed ID: 30328006
[TBL] [Abstract][Full Text] [Related]
20. Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.
Creighton CJ; Massarweh S; Huang S; Tsimelzon A; Hilsenbeck SG; Osborne CK; Shou J; Malorni L; Schiff R
Cancer Res; 2008 Sep; 68(18):7493-501. PubMed ID: 18794137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
